Access the full text.
Sign up today, get DeepDyve free for 14 days.
S. Harris, N. Watts, H. Genant, C. McKeever, T. Hangartner, Michael Keller, C. Chesnut, Jacques Brown, E. Eriksen, M. Hoseyni, D. Axelrod, P. Miller (1999)
Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.JAMA, 282 14
P. Steiger (1995)
Standardization of postero-anterior (PA) spine BMD measurements by DXA. Committee for Standards in DXA.Bone, 17 4
Bruce Ettinger, D. Black, B. Mitlak, R. Knickerbocker, Thomas Nickelsen, H. Genant, Claus Christiansen, P. Delmas, J. Zanchetta, J. Stakkestad, Kathryn Krueger, F. Cohen, Stephen Eckert, K. Ensrud, L. Avioli, Paul Lips, S. Cummings (1999)
Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.JAMA, 282 7
Paget ’ sdiseaseof
T. Wilkin (1999)
Changing perceptions in osteoporosis.BMJ, 318
P. Dolan, D. Torgerson (1998)
The Cost of Treating Osteoporotic Fractures in the United Kingdom Female PopulationOsteoporosis International, 8
S. Harris, N. Watts, R. Jackson, H. Genant, R. Wasnich, P. Ross, P. Miller, A. Licata, C. Chestnut (1993)
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy.The American journal of medicine, 95 6
T. England, J. Samsoondar, G. Maw (1994)
Evaluation of the Hybritech Tandem-R Ostase immunoradiometric assay for skeletal alkaline phosphatase.Clinical biochemistry, 27 3
P. Groen, D. Lubbe, L. Hirsch, A. Daifotis, W. Stephenson, D. Freedholm, Suzanne Pryor-Tillotson, M. Seleznick, H. Pinkas, Kenneth Wang (1996)
Esophagitis associated with the use of alendronate.The New England journal of medicine, 335 14
D. Hosking, R. Eusebio, A. Chines (1998)
Paget's disease of bone: reduction of disease activity with oral risedronate.Bone, 22 1
U. Liberman, S. Weiss, J. Broll, H. Minne, H. Quan, N. Bell, J. Rodriguez-Portales, R. Downs, J. Dequeker, M. Favus, E. Seeman, R. Recker, T. Capizzi, A. Santora, A. Lombardi, R. Shah, L. Hirsch, D. Karpf (1996)
Effect of Oral Alendronate on Bone Mineral Density and the Incidence of Fractures in Postmenopausal OsteoporosisObstetrical & Gynecological Survey, 51
Christian Roux, Philippe Ravaud, Martine Cohen-Solal, M. Vernejoul, S. Guillemant, B. Cherruau, Pierre Delmas, Maxime Dougados, Bernard Amor (1994)
Biologic, histologic and densitometric effects of oral risedronate on bone in patients with multiple myeloma.Bone, 15 1
D. Uebelhart, E. Gineyts, M. Chapuy, P. Delmas (1990)
Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease.Bone and mineral, 8 1
M. Forwood, David Burr, Y. Takano, D. Eastman, P. Smith, J. Schwardt (1995)
Risedronate treatment does not increase microdamage in the canine femoral neck.Bone, 16 6
D. Black, S. Cummings, D. Karpf, J. Cauley, D. Thompson, M. Nevitt, D. Bauer, H. Genant, W. Haskell, R. Marcus, S. Ott, J. Torner, S. Quandt, T. Reiss, K. Ensrud (1996)
Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fracturesThe Lancet, 348
J. Cauley, D. Seeley, K. Ensrud, B. Ettinger, D. Black, S. Cummings (1995)
Estrogen Replacement Therapy and Fractures in Older WomenAnnals of Internal Medicine, 122
R. Eastell (1998)
Treatment of postmenopausal osteoporosis.The New England journal of medicine, 338 11
M. Gcnant, ‘A SunFrancisco. (1995)
Development of formulas for standardized DXA measurementsJournal of Bone and Mineral Research, 10
Martine Cohen-Solal, Christian Roux, A. Valentin‐Opran, Maxime Dougados, Bernard Amor, M. Vernejoul (1992)
Histomorphometric effect of six month treatment with oral Risedronate in patients with multiple myeloma.Bone, 14 3
(1998)
Risedronate increasesbone mineral density at the hip, spine,and radius in postmenopausalwomen with low bone mass. [abstract
R. Boyce, C. Paddock, J. Gleason, W. Sletsema, E. Eriksen (1995)
The effects of risedronate on canine cancellous bone remodeling: Three‐dimensional kinetic reconstruction of the remodeling siteJournal of Bone and Mineral Research, 10
(1999)
Integratedsafetyanalysis of risedroantein postmenopausal women[abstract].Presentedat the 81st Annual Meeting of the EndocrineSociety,SanDiego, CA, June12–15,1999
MD Lufkin, MD Wahner, PhD O'Fallon, MD Hodgson, Mbbs Kotowicz, Mph Lane, MD Judd, MD Caplan, MD Riggs (1992)
Treatment of Postmenopausal Osteoporosis with Transdermal EstrogenAnnals of Internal Medicine, 117
R. Wielen, L. Groot, W. Staveren, M. Löwik, H. Berg, J. Haller, O. Moreiras (1995)
Serum vitamin D concentrations among elderly people in EuropeThe Lancet, 346
G. Maconi, G. Porro (1995)
Multiple ulcerative esophagitis caused by alendronate.The American journal of gastroenterology, 90 10
H. Genant, Chun-Ying Wu, C. Kuijk, M. Nevitt (1993)
Vertebral fracture assessment using a semiquantitative techniqueJournal of Bone and Mineral Research, 8
F. Mackay, L. Wilton, G. Pearce, S. Freemantle, R. Mann (1998)
United Kingdom experience with alendronate and oesophageal reactions.The British journal of general practice : the journal of the Royal College of General Practitioners, 48 429
F. Spivacow, J. Zanchetta, E. Kerzberg, A. Frigeri, R. Fiasché, E. Roldán (1996)
Tolerability of oral pamidronate in elderly patients with osteoporosis and other metabolic bone diseasesCurrent Therapeutic Research-clinical and Experimental, 57
C. Reasner, M. Stone, D. Hosking, A. Ballah, G. Mundy (1993)
Acute changes in calcium homeostasis during treatment of primary hyperparathyroidism with risedronate.The Journal of clinical endocrinology and metabolism, 77 4
(1999)
Pamidronate:an unrecognizedproblemin gastrointestinal tolerability
(1998)
Alendronateuseamong812 women:prevalenceof gastrointestinal complaints, noncompliancewith patient instructions, and discontinuation.J ManagedCarePharm1998;4:488–92
P. Miller, Jacques Brown, E. Siris, M. Hoseyni, D. Axelrod, P. Bekker (1999)
A comparative trial of risedronate vs. etidronate in the treatment of patients with Paget’s disease of boneBone, 24
Integratedsafetyanalysis of risedroantein postmenopausalwomen [ abstract ]
The purpose of this randomized, double-masked, placebo-controlled study was to determine the efficacy and safety of risedronate in the prevention of vertebral fractures in postmenopausal women with established osteoporosis. The study was conducted at 80 study centers in Europe and Australia. Postmenopausal women (n= 1226) with two or more prevalent vertebral fractures received risedronate 2.5 or 5 mg/day or placebo; all subjects also received elemental calcium 1000 mg/day, and up to 500 IU/day vitamin D if baseline levels were low. The study duration was 3 years; however, the 2.5 mg group was discontinued by protocol amendment after 2 years. Lateral spinal radiographs were taken annually for assessment of vertebral fractures, and bone mineral density was measured by dual-energy X-ray absorptiometry at 6-month intervals. Risedronate 5 mg reduced the risk of new vertebral fractures by 49% over 3 years compared with control (p<0.001). A significant reduction of 61% was seen within the first year (p= 0.001). The fracture reduction with risedronate 2.5 mg was similar to that in the 5 mg group over 2 years. The risk of nonvertebral fractures was reduced by 33% compared with control over 3 years (p= 0.06). Risedronate significantly increased bone mineral density at the spine and hip within 6 months. The adverse-event profile of risedronate, including gastrointestinal adverse events, was similar to that of control. Risedronate 5 mg provides effective and well-tolerated therapy for severe postmenopausal osteoporosis, reducing the incidence of vertebral fractures and improving bone density in women with established disease.
Osteoporosis International – Springer Journals
Published: Jan 1, 2000
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.